Retatrutide: reworking hormone signals
Glucagon usually raises blood glucose. Incorporating its receptor into a metabolic peptide is a bolder piece of redesign than “another weight-loss drug” suggests.
Why bring glucagon into it?
Retatrutide is an engineered peptide active at GIP, GLP-1 and glucagon receptors. The pharmacology review describes the argument: combine appetite and insulin effects with glucagon-related energy expenditure and lipid metabolism. Glucagon normally promotes release of glucose from the liver, so its inclusion in a diabetes programme initially sounds perverse to me. The combination is intended to balance that activity with the insulin-promoting effects of the other receptor signals.
This is molecular engineering using earlier hormone biology. Retatrutide remains investigational, in Phase 3 development, with no FDA approval or approval by another regulator.
Receptor experiments
The 2024 structural and cell-assay study resolved retatrutide bound to each receptor and compared its signalling potency with the corresponding natural hormones. The activities were uneven: about 8.9 times native GIP at GIPR, and 0.3 and 0.4 times native glucagon and GLP-1 at their respective receptors.
These are laboratory comparisons with different reference hormones. They cannot be added into an overall potency score, or used to predict a person’s weight change. I regard the asymmetry as evidence of a designed molecule; the trials have to establish what that design accomplishes.
Phase 2 obesity and diabetes trials
In the obesity trial of 338 adults, the 12 mg study group had a mean body-weight reduction of 24.2% at 48 weeks, versus 2.1% with placebo. Gastrointestinal adverse events were dose-related, and heart rate increased in a dose-dependent pattern that peaked around 24 weeks.
The separate Phase 2 trial in 281 adults with type 2 diabetes reported a 2.02-percentage-point reduction in HbA1c at 24 weeks in the 12 mg group. HbA1c is a measure of longer-term blood glucose. The study’s body-weight result was measured at 36 weeks. Keeping those dates attached matters: a later weight measurement cannot be passed off as a result from the earlier glucose assessment.
MRI measurement of liver fat
The liver-fat substudy enrolled 98 adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease, without type 2 diabetes. At 24 weeks, the 12 mg study group had an 82.4% relative reduction in liver fat, and 86% reached liver fat below 5%.
The liver-fat measurement is persuasive precisely because its ambition stays specific. Its meaning remains specific: MRI-measured fat content. The result establishes neither disappearance of every feature of liver disease nor a clinical approval for treatment. It is a reason to continue the investigation.
Safety and the unverified supply
The Phase 2 clinical record leaves the longer-term cardiovascular significance of the heart-rate increase unresolved. Nausea, vomiting, diarrhoea and constipation are central tolerability concerns. The review places those questions alongside the ongoing Phase 3 programme. Products circulating outside trials have unverified identity, purity and sterility.
Community descriptions of quieted food thoughts, warmth, a faster pulse or sleep disturbance are anecdotal and supply no clinical evidence about those products. A feeling of warmth also cannot establish a glucagon-mediated mechanism in an individual. I want retatrutide’s engineering judged under trial conditions; the GHK-Cu pairing question concerns an additional, untested proposal.